Andreas Klatt

Dr. Andreas Klatt

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2008 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
AKAndreas Klatt
Andreas Klatt
BPBrigitte Paul‐Klausch
Brigitte Paul‐Klausch
GKGabriele Klinger
Gabriele Klinger
GKGetrud Kühn
Getrud Kühn
JRJoerg H. Renno
Joerg H. Renno
KWKlaus Wielckens
Klaus Wielckens
We report a process that results in the acceleration of matrix degradation in human articular cartilage, a phenomenon commonly observed in osteoarthritis (OA). The study was conducted by (1) examining the potential of collagen II in modulating the gene expression profile of primary human chondrocytes (PHCs), and (2) investigating the involvement of pro‐inflammatory signaling cascades. We first tested the collagen II‐dependent induction of pro‐inflammatory cytokines and matrix metalloproteinases (MMPs) in PHCs. PHCs were incubated with or without monomeric (i.e., nonfibrillar) collagen II. Cells were then analyzed by RT‐PCR for the expression of MMP1, MMP3, MMP13, MMP14, and IL‐1β. ELISA was used to quantify IL‐6 and IL‐8 release. To examine the influence of collagen II signaling, specifically the role of MAPK p38, a p38‐inhibitor was added prior to collagen treatment. Changes in IκB concentration were monitored by immunoblot analysis to detect NFκB signaling. Results indicated that incubation of PHCs with collagen II did produce a dose‐dependent induction of MMP1, MMP3, MMP13, MMP14, as well as cytokines IL‐1β, IL‐6, and IL‐8. At the same time, inhibition of p38 and IκB degradation revealed that collagen II‐dependent gene induction also involves MAPK p38 and NFκB signaling. Thus, we provide evidence for a collagen II‐dependent feed‐forward mechanism whereby collagen II induces first MMPs and pro‐inflammatory cytokines and then release of collagen II fragments from mature collagen II fibers. This, in turn, induces more pro‐inflammatory cytokines and MMPs, and the process is repeated, which results in the acceleration and perpetuation of cartilage matrix degradation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:65–70, 2009

17 October 2009 in FEBS Letters
Verified
Journal Article
Closed access
AKAndreas Klatt
Andreas Klatt
GKGabriele Klinger
Gabriele Klinger
BPBrigitte Paul-Klausch
Brigitte Paul-Klausch
GKGertrud Kühn
Gertrud Kühn
JRJoerg H. Renno
Joerg H. Renno
KWKlaus Wielckens
Klaus Wielckens

29 January 2009 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
AKAndreas Klatt
Andreas Klatt
DZDagmar Zech
Dagmar Zech
GKGertrud Kühn
Gertrud Kühn
BPBrigitte Paul‐Klausch
Brigitte Paul‐Klausch
GKGabriele Klinger
Gabriele Klinger
KWKlaus Wielckens
Klaus Wielckens

1 January 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DLDaniela Lau
Daniela Lau
DEDzemal Elezagic
Dzemal Elezagic
GHGabriele Hermes
Gabriele Hermes
MMMatthias Mörgelin
Matthias Mörgelin
AWAlexander P. Wohl
Alexander P. Wohl
AKAndreas Klatt
Andreas Klatt
C-type lectin domain family 3 member A (CLEC3A) is a poorly characterized protein belonging to the superfamily of C-type lectins. Its closest homologue tetranectin binds to the kringle 4 domain of plasminogen and enhances its association with tissue plasminogen activator (tPA) thereby enhancing plasmin production, but whether CLEC3A contributes to plasminogen activation is unknown. Here, we recombinantly expressed murine and human full-length CLEC3As as well as truncated forms of CLEC3A in HEK-293 EBNA cells. We analyzed the structure of recombinant CLEC3A by SDS-PAGE and immunoblot, glycan analysis, matrix-assisted laser desorption ionization-time of flight mass spectrometry, size-exclusion chromatography, circular dichroism spectroscopy, and electron microscopy, compared the properties of the recombinant protein with those of CLEC3A extracted from cartilage, and investigated its tissue distribution and extracellular assembly by immunohistochemistry and immunofluorescence microscopy. We found that CLEC3A mainly occurs as a monomer, but also forms dimers and trimers, potentially via a coiled-coil α-helix. We also noted that CLEC3A can be modified with chondroitin/dermatan sulfate side chains and tends to oligomerize to form higher aggregates. We show that CLEC3A is present in resting, proliferating, and hypertrophic growth-plate cartilage and assembles into an extended extracellular network in cultures of rat chondrosarcoma cells. Further, we found that CLEC3A specifically binds to plasminogen and enhances tPA-mediated plasminogen activation. In summary, we have determined the structure, tissue distribution, and molecular function of the cartilage-specific lectin CLEC3A and show that CLEC3A binds to plasminogen and participates in tPA-mediated plasminogen activation.

2 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAnnika Roth
Annika Roth
SLSteffen Luetke
Steffen Luetke
DMDenise Meinberger
Denise Meinberger
GHGabriele Hermes
Gabriele Hermes
GSGerhard Sengle
Gerhard Sengle
AKAndreas Klatt
Andreas Klatt
Objective: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen accountable for the coronavirus disease 2019 (COVID-19) pandemic. Viral entry via binding of the receptor binding domain (RBD) located within the S1 subunit of the SARS-CoV-2 Spike (S) protein to its target receptor angiotensin converting enzyme (ACE) 2 is a key step in cell infection. The efficient transition of the virus is linked to a unique protein called open reading frame (ORF) 8. As SARS-CoV-2 infections can develop into life-threatening lower respiratory syndromes, effective therapy options are urgently needed. Several publications propose vitamin D treatment, although its mode of action against COVID-19 is not fully elucidated. It is speculated that vitamin D’s beneficial effects are mediated by up-regulating LL-37, a well-known antimicrobial peptide with antiviral effects. Methods: Recombinantly expressed SARS-CoV-2 S protein, the extended S1 subunit (S1e), the S2 subunit (S2), the receptor binding domain (RBD), and ORF8 were used for surface plasmon resonance (SPR) studies to investigate LL-37’s ability to bind to SARS-CoV-2 proteins and to localize its binding site within the S protein. Binding competition studies were conducted to confirm an inhibitory action of LL-37 on the attachment of SARS-CoV-2 S protein to its entry receptor ACE2. Results: We could show that LL-37 binds to SARS-CoV-2 S protein (LL-37/S Strep K D = 410 nM, LL-37/S His K D = 410 nM) with the same affinity, as SARS-CoV-2 binds to hACE2 (hACE2/S Strep K D = 370 nM, hACE2/S His K D = 370 nM). The binding is not restricted to the RBD of the S protein, but rather distributed along the entire length of the protein. Interaction between LL-37 and ORF8 was detected with a K D of 290 nM. Further, inhibition of the binding of S Strep (IC 50 = 740 nM), S1e (IC 50 = 170 nM), and RBD (IC 50 = 130 nM) to hACE2 by LL-37 was demonstrated. Conclusions: We have revealed a biochemical link between vitamin D, LL-37, and COVID-19 severity. SPR analysis demonstrated that LL-37 binds to SARS-CoV-2 S protein and inhibits binding to its receptor hACE2, and most likely viral entry into the cell. This study supports the prophylactic use of vitamin D to induce LL-37 that protects from SARS-CoV-2 infection, and the therapeutic administration of vitamin D for the treatment of COVID-19 patients. Further, our results provide evidence that the direct use of LL-37 by inhalation and systemic application may reduce the severity of COVID-19.

26 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DMDenise Meinberger
Denise Meinberger
MKManuel Koch
Manuel Koch
ARAnnika Roth
Annika Roth
GHGabriele Hermes
Gabriele Hermes
JSJannik Stemler
Jannik Stemler
AKAndreas Klatt
Andreas Klatt
Immunoassays are a standard diagnostic tool that assesses immunity in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. However, immunoassays do not provide information about contaminating antigens or cross-reactions and might exhibit inaccurately high sensitivity and low specificity. We aimed to gain insight into the serological immune response of SARS-CoV-2 patients by immunoblot analysis. We analyzed serum immunoglobulins IgM, -A, and -G directed against SARS-CoV-2 proteins by immunoblot analysis from 12 infected patients. We determined IgG isotype antibodies by commercially available ELISA and assessed the clinical parameters of inflammation status and kidney and liver injury. Unexpectedly, we found no correlation between the presence of antibodies and the future course of the disease. However, attention should be paid to the parameters CRP, IL-6, and LDH. We found evidence of antibody cross-reactivity, which questions the reliability of results for serum samples that tested negative for anti-SARS-CoV-2 antibodies when assessed by immunoassays. Nevertheless, for the detection of IgG anti-SARS-CoV-2 antibodies, our data suggest that the use of the spike glycoprotein in immunoassays should be sufficient to identify positive patients. Using a combination of the spike glycoprotein and the open reading frame 8 protein could prove to be the best way of detecting anti-SARS-CoV-2 IgM antibodies.